跳至主要内容
临床试验/NCT01341886
NCT01341886已完成不适用

Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer

Mashhad University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2010年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
51
试验地点
1
主要终点
TSH

研究概览

简要总结

Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine treatment. Levothyroxine causes increased thyroid hormones which can have negative impact on bone and cardiovascular system. Anecdotal reports have shown that metformin can induce TSH suppression without change in T3 and T4 concentration. The purpose of this study was to prescribe metformin as additional drug to levothyroxin in order to decrease levothyroxine dosage.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • papillary or follicular thyroid cancer
  • stage 1 or 2 according to TNM system version 6
  • surgery and radioiodine treatment
  • levothyroxine suppression treatment

排除标准

  • cardiopulmonary failure
  • liver failure
  • renal failure
  • pregnancy
  • drugs (colestyramin, sucralfate, phenobarbital, phenytoin, carbamazepin, rifampin, amiodarone, chloroquin, androgens, sertraline, frusemide, heparin)

研究组 & 干预措施

metformin

Active Comparator

patients who receive metformin in addition to levothyroxine

干预措施: Metformin (Drug)

levothyroxine

Placebo Comparator

patients who receive only levothyroxine

干预措施: Metformin (Drug)

结局指标

主要结局

TSH

时间窗: 3 months

次要结局

  • freeT3,freeT4(3months)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验